Published on 29 October 2013
Suggested evaluation of biological drugs role for WHO – Editor’s response
Author(s): Professor Philip D Walson, MD
biological products, pegylated interferons, WHO
DOI: 10.5639/gabij.2013.0204.043
13.306 views
Published on 29 October 2013
Author(s): Professor Philip D Walson, MD
biological products, pegylated interferons, WHO
DOI: 10.5639/gabij.2013.0204.043
13.306 views
Published on 05 December 2013
Author(s): Professor Philip D Walson, MD
DOI: 10.5639/gabij.2013.0204.042
11.603 views
Published on 04 December 2013
Author(s): GaBI Journal Editor
DOI: 10.5639/gabij.2013.0203.041
8.932 views
Published on 06 August 2013
Author(s): GaBI Journal Editor
biologicals, biosimilars substitution, state legislation
DOI: 10.5639/gabij.2013.0203.040
14.330 views
Published on 11 June 2013
Author(s): Professor David A Power, MD, PhD, FRCP, FRACP
Australia, biosimilars, pharmaceutical benefits scheme, TGA
DOI: 10.5639/gabij.2013.0203.030
18.342 views
Published on 24 April 2013
Author(s): Angela Vogt-Eisele, PhD, Professor Marietta Kaszkin-Bettag, PhD, Tilo Netzer, PhD, Wolfram Hildebrandt, MSc, MA, Tobias Blank, PhD
biosimilar regulation, biosimilar safety (EU USA), biosimilar toxicity, immunogenicity, pharmacovigilance, traceability
DOI: 10.5639/gabij.2013.0203.039
35.008 views
Published on 25 September 2013
Author(s): Andrew Mica, MBA, et al.
biological, drug shortages, healthcare provider, manufacturing, supply chain
DOI: 10.5639/gabij.2013.0203.038
41.672 views
Published on 24 April 2013
Author(s): et al., Shih-Ting Chiu, MSc
extra-reference design, generalized pivotal quantity, individual bioequivalence, replicated crossover design
DOI: 10.5639/gabij.2013.0203.037
26.631 views
Published on 22 April 2013
Author(s): Alessandro Curto, MSSc, Katelijne Van de Vooren, MSc, Professor Livio Garattini, Roberta Lo Muto, MSc, Silvy Duranti, MBA
biosimilars, competition, Italy, regions, tender
DOI: 10.5639/gabij.2013.0203.036
19.801 views
Published on 11 June 2013
Author(s): et al., Frank Mueller, MSc
fermentation, hansenula polymorpha, parathyroid hormone fragment, recombinant protein, rPTH 1-34
DOI: 10.5639/gabij.2013.0203.035
21.793 views
Published on 12 June 2013
Author(s): Brian Godman, BSc, PhD
demand-side measures, generics, renin-angiotensin inhibitor drugs, Srpska, statins, supply-side measures
DOI: 10.5639/gabij.2013.0203.029
12.611 views
Published on 11 June 2013
Author(s): Professor Andrea Laslop, MD
biosimilars, comparability, extrapolation, monoclonal antibodies, switching
DOI: 10.5639/gabij.2013.0203.034
27.237 views